Fusion Antibodies plc Stock: price and insider trades · United Kingdom
No insider purchase over the last 90 days. The latest, by Adrian Kinkaid, was filed 06 May 2025.
Fusion Antibodies plc: what insiders have been doing
Fusion Antibodies plc, classified in the Health Care sector, is a listed company. Its insiders report their share dealings to RNS (LSE). In the past year (21 October 2025 to 21 October 2026), 1 filing came from 1 insider.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
With 1 filing in twelve months, the company is quieter than the median of 6 filings across the 832 companies we follow on the same exchange. Looking back to 2018, when coverage begins, insiders filed 23 purchases and 3 sales.
There has been no open-market purchase by an insider of Fusion Antibodies plc for at least a year.
This summary is built from RNS (LSE) disclosures alone and does not predict where the share price will go.
Who traded when
BuySaleSince the insiders bought
- +126.9%Entry £0.06 · Close at T+365 £0.14
- +392.3%Entry £0.03 · Close at T+365 £0.16
- +165.3%Entry £0.03 · Close at T+365 £0.09
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Fusion Antibodies plc Strong Buy (bullish).
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended March 2026 · cache
- 200,000 sharesOutside a trading venueISIN GB00BDQZGK16RNS:625c20a4-5316-4800-9ba1-a770f1f5960e
- 0Outside a trading venueISIN GB00BDQZGK16RNS:5733815
- 100,000 shares@ £0.061833.4% of flowXLON, London Stock ExchangeISIN GB00BDQZGK16RNS:5642517Canonical exit: 4 Aug 2025 (T+90)
- 83,728 shares@ £0.041919.2% of flowXLON, London Stock ExchangeISIN GB00BDQZGK16RNS:5392116Canonical exit: 14 Jan 2025 (T+90)
- 94,825 shares@ £0.032838.9% of flowXLON, London Stock ExchangeISIN GB00BDQZGK16RNS:5341314Canonical exit: 8 Dec 2024 (T+90)
- 120,000 shares@ £0.031720.7% of flowXLON, London Stock ExchangeISIN GB00BDQZGK16RNS:5337535Canonical exit: 4 Dec 2024 (T+90)
- 150,000 shares@ £0.032149.5% of flowXLON, London Stock ExchangeISIN GB00BDQZGK16RNS:5275959Canonical exit: 20 Oct 2024 (T+90)
- 100,565 shares@ £0.049650.5% of flowXLON, London Stock ExchangeISIN GB00BDQZGK16RNS:4991240-0Canonical exit: 3 Mar 2024 (T+90)
- 101,847 shares@ £0.04926.7% of flowXLON, London Stock ExchangeISIN GB00BDQZGK16RNS:4991240-1Canonical exit: 3 Mar 2024 (T+90)
- 68,750 shares@ £0.07261.1% of flowXLON, London Stock ExchangeISIN GB00BDQZGK16RNS:4799444Canonical exit: 7 Sept 2023 (T+90)
- 10,000 shares@ £0.4191XLON, London Stock ExchangeISIN GB00BDQZGK16FCA-NSM:4563073Canonical exit: 29 Jan 2023 (T+90)
- 4,000 shares@ £0.53910.1% of flowLondon Stock Exchange, XLONISIN GB00BDQZGK16FCA-NSM:4515499Canonical exit: 19 Dec 2022 (T+90)
- 8,875 shares@ £0.0124London Stock Exchange, XLONISIN GB00BDQZGK16FCA-NSM:3854914
- 20,000 shares@ £0.018London Stock Exchange, XLONISIN GB00BDQZGK16FCA-NSM:3727827
- 20,000 shares@ £0.60100.0% of flowLondon Stock Exchange, XLONISIN GB00BDQZGK16FCA-NSM:LSE20200317070008_3528937_20200331164957099_17551Canonical exit: 14 Jun 2020 (T+90)
- 20,000 shares@ £0.8267.4% of flowLondon Stock Exchange, XLONISIN GB00BDQZGK16FCA-NSM:LSE20200203120143_3482003_20200331164938547_1086
- 20,000 shares@ £0.7723.9% of flowLondon Stock Exchange, XLONISIN GB00BDQZGK16FCA-NSM:LSE20200110114754_14379874_20200331164951868_9774Canonical exit: 7 Apr 2020 (T+90)
- 20,000 shares@ £0.7523.2% of flowLondon Stock Exchange, XLONISIN GB00BDQZGK16FCA-NSM:LSE20191203092614_14332734_20200326185106334_28730Canonical exit: 1 Mar 2020 (T+90)
- 15,000 shares@ £0.6545.2% of flowLondon Stock Exchange, XLONISIN GB00BDQZGK16FCA-NSM:LSE20190926095422_14242712_20200326185201885_4999Canonical exit: 25 Dec 2019 (T+90)
- 6,920 shares@ £0.72983.1% of flowLondon Stock Exchange, XLONISIN GB00BDQZGK16FCA-NSM:LSE20190703160914_14135577_20200326185125204_34467-0Canonical exit: 30 Sept 2019 (T+90)
- 10,000 shares@ £0.5916.4% of flowLondon Stock Exchange, XLONISIN GB00BDQZGK16FCA-NSM:LSE20190703160914_14135577_20200326185125204_34467-1Canonical exit: 30 Sept 2019 (T+90)
- 30,000 shares@ £0.695100.0% of flowLondon Stock Exchange, XLONISIN GB00BDQZGK16FCA-NSM:LSE20190703160914_14135577_20200326185125204_34467-2Canonical exit: 30 Sept 2019 (T+90)
- 1,290 shares@ £0.77100.0% of flowLondon Stock Exchange, XLONISIN GB00BDQZGK16FCA-NSM:LSE20190429144627_14055876_20200326185040667_1701Canonical exit: 28 Jul 2019 (T+90)
- 5,000 shares@ £0.52510.8% of flowLondon Stock Exchange, XLONISIN GB00BDQZGK16FCA-NSM:LSE20181203133902_13889315_20200330111407806_1258Canonical exit: 28 Feb 2019 (T+90)
- 8,500 shares@ £0.6718.9% of flowLondon Stock Exchange, XLONISIN GB00BDQZGK16FCA-NSM:LSE20180925142357_13804051_20200330111446177_4543-0Canonical exit: 23 Dec 2018 (T+90)
25 of 28 declarations
About Fusion Antibodies plc
Fusion Antibodies plc is a company focused on the development of therapeutic antibodies. It is listed on the London Stock Exchange (XLON).
